In oncotherapy, protein kinases inhibitors constitute a main continuously growing category of targeted chemotherapies that is free of the traditional cancer chemotherapy common side actions as they target the signalling pathways and microenvironment of the cancer cells with minor adverse actions on normal mammalian cells.13–16. Here, WEE1 is linked to cancer.